ImmunoGen Inc. (NASDAQ: IMGN) is -4.21% lower on its value in year-to-date trading and has touched a low of $1.95 and a high of $7.07 in the current 52-week trading range. The IMGN stock was last observed hovering at around $4.89 in the recent trading session, with the current gains setting it 0.05% off its average median price target of $6.38 for the next 12 months. It is also 58.83% off the consensus price target high of $12.00 offered by 9 analysts, but current levels are -23.5% lower than the price target low of $4.00 for the same period.
Gold bugs are shouting from the rooftops in excitement, but that doesn’t mean you rush out and just buy any gold stock…That’s why we laid out The 2021 Ultimate Gold Portfolio – to dissect the treasure from the trash.
At last check, trading at $4.94, the stock is 7.74% and 9.68% above its SMA20 and SMA50 respectively. However, with a current trading volume of 0.44 million and changing 1.02% at the moment leaves the stock 24.44% off its SMA200. IMGN registered 104.60% gain for a year compared to 6-month loss of 5.62%. The firm has a 50-day simple moving average (SMA 50) of $4.7015 and a 200-day simple moving average (SMA200) of $4.3766.
The stock witnessed a 6.54% gain in the last 1 month and extending the period to 3 months gives it a 42.98%, and is 13.72% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 6.64% over the week and 6.86% over the month.
ImmunoGen Inc. (IMGN) has around 75 employees, a market worth around $830.08M and $87.00M in sales. Distance from 52-week low is 153.33% and -30.13% from its 52-week high. The company has generated returns on investments over the last 12 months (124.60%).
ImmunoGen Inc. (IMGN) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for ImmunoGen Inc. (IMGN) is a “Overweight”. 9 analysts offering their recommendations for the stock have an average rating of 2.20, where 4 rate it as a Hold and 0 think it is a “Overweight”. 5 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
ImmunoGen Inc. is expected to release its quarterly report on 07/24/2020 and quarterly earnings per share for the current quarter are estimated at -$0.17 with sales reaching $14.73M over the same period.The EPS is expected to grow by 41.80% this year, but quarterly earnings will post -23.30% year-over-year.
ImmunoGen Inc. (IMGN) Top Institutional Holders
262 institutions hold shares in ImmunoGen Inc. (IMGN), with 1.94M shares held by insiders accounting for 1.11% while institutional investors hold 77.47% of the company’s shares. The shares outstanding are 166.95M, and float is at 145.38M with Short Float at 8.20%. Institutions hold 76.61% of the Float.
The top institutional shareholder in the company is Wellington Management Company, LLP with over 19.15 million shares valued at $65.31 million. The investor’s holdings represent 10.98% of the IMGN Shares outstanding. As of Mar 30, 2020, the second largest holder is Redmile Group, LLC with 16.73 million shares valued at $57.06 million to account for 9.59% of the shares outstanding. The other top investors are Vanguard Group, Inc. (The) which holds 16.04 million shares representing 9.20% and valued at over $54.71 million, while Blackrock Inc. holds 7.81% of the shares totaling 13.62 million with a market value of $46.45 million.
ImmunoGen Inc. (IMGN) Insider Activity
A total of 12 insider transactions have happened at ImmunoGen Inc. (IMGN) in the last six months, with sales accounting for 6 and purchases happening 6 times. The most recent transaction is an insider sale by FOSTER DAVID G, the company’s V.P.-Fin., Prin. Acctg. Off. SEC filings show that FOSTER DAVID G sold 5,448 shares of the company’s common stock on Apr 02 at a price of $3.43 per share for a total of $18687.0. Following the sale, the insider now owns 21382.0 shares.
ImmunoGen Inc. disclosed in a document filed with the SEC on Feb 24 that Ryll Thomas (SVP, Technical Operations) sold a total of 16,790 shares of the company’s common stock. The trade occurred on Feb 24 and was made at $4.99 per share for $83782.0. Following the transaction, the insider now directly holds 75624.0 shares of the IMGN stock.
Still, SEC filings show that on Feb 24, Berkenblit Anna (SVP & Chief Medical Officer) disposed off 25,803 shares at an average price of $4.99 for $0.13 million. The insider now directly holds 98,089 shares of ImmunoGen Inc. (IMGN).
ImmunoGen Inc. (IMGN): Who are the competitors?
The company’s main competitors (and peers) include Eli Lilly and Company (LLY) that is trading 47.93% up over the past 12 months. Bristol-Myers Squibb Company (BMY) is 31.16% up on the 1-year trading charts. Short interest in the company’s stock has fallen -7.47% from the last report on May 14, 2020 to stand at a total of 12.81 million short shares sold with a short interest ratio of 4.87.